Chemo and radiation for low rectal cancer, aiming to avoid surgery
Part of Cancer, Digestive system clinical trials.
This trial tests whether people with early- to intermediate-stage low rectal cancer can avoid surgery if their tumor responds well to a full course of chemotherapy and radiation. It starts with brief chemotherapy, then adjusts treatment based on how much the tumor shrinks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- Your rectal cancer is a common type (pMMR/MSS) and it's not too advanced (stage T1 to T3b, no spread to distant organs).
- The bottom edge of your tumor is within about 2 inches (5 cm) of the anal opening.
- The tumor is no more than 2 inches long and involves less than two-thirds of the rectum's width.
- You are willing to receive chemotherapy (XELOX), radiation, and more chemotherapy, and then possibly avoid surgery if the tumor disappears.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (enverolimab plus standard chemotherapy) given before surgery for very low rectal cancer. The goal is to shrink the tumor so much that patients may avoid surgery and keep their rectum, but the study is for those who haven't had treatment before.
This trial tests whether combining chemotherapy with high-dose radiation guided by MRI (a special scan) can better treat low rectal cancer. It may help shrink the tumor and improve local control while targeting the tumor more precisely.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a combination of immunotherapy (tislelizumab) and standard chemotherapy and radiation before surgery for low rectal cancer. The goal is to help shrink or eliminate the tumor so surgery might be less invasive or not needed, allowing you to keep your rectum.
This trial tests a combination of chemotherapy and radiation therapy before surgery for people with mid or low rectal cancer that hasn't spread. The goal is to see if this approach works better than current treatments.
This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.